EGFR and neoplasm: ERBB2 amplification has been identified as a resistance mechanism induced upon treatment with erlotinib or gefitinib (39, 40) and was observed in 12% of tumor samples obtained from patients at resistance to EGFR TKI therapy (41); however, its role in afatinib resistance is unclear.